BioSpace News Archive

Human Immunology Biosciences (HI-Bio™) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for felzartamab for the treatment of antibody-mediated rejection (AMR) in kidney transplant recipients.

Accent Therapeutics, a biopharmaceutical company pioneering a new class of small molecule precision cancer therapies, today announced four upcoming presentations and posters at the 2024 American Association for Cancer Research (AACR) Annual Meeting, taking place April 5-10 in San Diego, California.

TriSalus Life Sciences® Inc. (Nasdaq: TLSI) announced today that the Company will present data from recent research findings at the 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting, to be held March 23-28, 2024, in Salt Lake City, Utah.

ENDRA Life Sciences Inc. today announced that the company will report financial results for the three months and year ended December 31, 2023 on Thursday, March 28, 2024 after the close of trading on the U.S. financial markets.

Public Health Vaccines, LLC (PHV) has started its Phase 1 clinical trial (NCT06265012) to evaluate the safety and immunogenicity of the company’s single-dose vaccine (PHV01) against Marburg virus - a hemorrhagic fever virus of the Filoviridae family that causes Marburg virus disease, a rare but severe hemorrhagic fever that affects people and non-human primates and has a case fatality rate of up to 88%.

Yield10 Bioscience, Inc. announced that USDA-APHIS’s Biotechnology Regulatory Services has determined that Yield10’s Camelina sativa varieties developed using genetic engineering to produce omega-3 fatty acids are not subject to the regulations under 7 CFR part 340, and may be grown and bred in the United States.

Dyadic International, Inc. today announced that Joseph Hazelton, Chief Business Officer and Doug Pace, Executive Vice President of Business Development will be attending the Future Food-Tech “Innovation & Investment from Farm to Fork” event March 21 – 22, 2024 at the San Francisco Marriott Marquis in California.

Capricor Therapeutics diseases, today announced that the Company is scheduled to present at two upcoming investor conferences.

ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company developing therapeutic solutions in Oncology/Hematology, Neurology, and Ophthalmology, announced that one of its subsidiaries, AiBtl BioPharma Inc., entered into an Agreement to exchange a 100% ownership stake in certain real estate for 1,533,333 shares of AIBL stock at $5 per share.

VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”) today announced it will host a conference call on Tuesday, March 26 at 8.30 a.m. U.S. Eastern Time to discuss its financial and operating results for the fourth quarter and full year 2023, in addition to providing a business update.